ACM
TVTX icon

Aster Capital Management’s Travere Therapeutics TVTX Stock Holding History

Aster Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,329
Closed -$49.8K – 1584
2025
Q1 		$49.8K Buy
2,329
+2,060
+766% +$41.8K 0.01% 824
2024
Q4 		$4.69K Buy
+269
New +$4.76K ﹤0.01% 868

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Aster Capital Management's TVTX Position: Q2 2025 in Review

Aster Capital Management sold out of Travere Therapeutics (TVTX) in Q2 2025, closing a stake of 2,329 shares — an estimated $49.8K sold.

Aster Capital Management first reported a position in TVTX in Q4 2024 and held it in 2 quarters. The position peaked at $49.8K in Q1 2025. 211 funds tracked by Wall St. Rank hold TVTX as of Q2 2025.

  • Aster Capital Management reported no remaining Travere Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Aster Capital Management sold 2,329 Travere Therapeutics shares in Q2 2025, an estimated $49.8K.
  • Aster Capital Management first reported a position in Travere Therapeutics in Q4 2024 and held it in 2 quarters.
  • Aster Capital Management's Travere Therapeutics position peaked at $49.8K in Q1 2025.
  • 211 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2025.

Based on Aster Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.